Fanastomig
Based on 1 Customer Validation
Fanastomig (EMB-02) is a bispecific antibody against PD-1/LAG3. Fanastomig exhibits potential immune checkpoint inhibitory activity and antineoplastic activity.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.478%
- CAS. Nr.: 2761795-00-8
- Molecular Weight:191.337 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
VK-CK-VH-CH1-h-CH2-CH3_L-kappa_Fab-G1-kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
PDCD1 & LAG3
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
VK-CK-VH-CH1-h-CH2-CH3_L-kappa_Fab-G1-kappa
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized PD-1 Protein, Human (147a.a, HEK293, His, HY-P70766) can bind Fanastomig. The EC50 for this effect is 3.686 ng/mL. -
Immobilized LAG-3 Protein, Human (HEK293, His, HY-P70722) can bind Fanastomig. The EC50 for this effect is 4.675 ng/mL. -
Flow cytometric analysis of 1X106 Juakat cells with Fanastomig (HY-P990740, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black). -
Flow Cytometry analysis of Raji cells labelling LAG3 (red) with Fanastomig (anti-LAG3) (HY-P990740). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS. Nr. 2761795-00-8
-
Appearance Liquid
-
Molecular Weight 191.337 kDa
-
Color Colorless to light yellow
-
Synonyms
EMB-02
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
Reinheit & Dokumentation
-
Data Sheet (253 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Fanastomig
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)